Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2013

View Archived Issues

New antiviral agents prepared by GlaxoSmithKline

Jazz Pharmaceuticals announces licensing agreement

Vertex begins pivotal phase III lumacaftor/ivacaftor study

Ampio Pharmaceuticals begins Optina trial in diabetic macular edema

Inviragen advances DENVax into second stage of phase II trial

Lupin prepares new agents for HCV infection

SB-010 proves to be well tolerated in three distinct phase I trials

Takeda and Resolve Therapeutics enter partnership

Team describes methods to derive toolboxes of macrocyclic compounds

Vildagliptin approval expanded in Japan

Biosimilar of filgrastim approved in Japan

Novel coagulation factor XIa inhibitors patented by Bristol-Myers Squibb

Dainippon Sumitomo Pharma obtains additional indication approval for Surepost in Japan

HanAll BioPharma presents new AMPK activators

QRx Pharma resubmits MoxDuo NDA to the FDA

Ventana and Biocare Medical sign license agreement for diagnosis of prostate lesions

Burkholderia mallei mutant shows promise as a live attenuated vaccine

Korean group prepares novel 11-beta-HSD-1 inhibitors

ViiV Healthcare grants voluntary license to increase access to HIV medicine for children

Ceptaris resubmits NDA for proprietary gel formulation of chemotherapeutic agent

Immune response to intradermal flu vaccine evaluated in patients with atopic dermatitis

Sylentis commences phase II trial with SYL-1001

European Commission approves Ilaris in acute gouty arthritis indication

FDA approves once-monthly intramuscular depot formulation of aripiprazole

Hyperion's Ravicti now available in U.S.

Lundbeck's Selincro approved in E.U. for alcohol dependence

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...